^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    TMPRSS2 inhibitor

    Related drugs:
    15d
    Single Dose Study, Pharmacokinetics of Oxycodone and PF614 Co-Administered With Nafamostat (PF614-MPAR-102) (clinicaltrials.gov)
    P1, N=54, Recruiting, Ensysce Biosciences | N=30 --> 54 | Trial completion date: Dec 2026 --> Apr 2027 | Trial primary completion date: Jul 2026 --> Dec 2026
    Enrollment change • Trial completion date • Trial primary completion date
    2ms
    Comparison of Anticoagulant Efficacy of Different Doses of Nafamostat Mesylate in Continuous Renal Replacement Therapy (CRRT) in the ICU (ChiCTR2600121852)
    P=N/A, N=92, Zhujiang Hospital of Southern Medical University; Zhujiang Hospital of Southern Medical University
    New trial
    |
    nafamostat
    2ms
    Effect of Regional Citrate Anticoagulation Combined with Nafamostat Mesylate on Extracorporeal Circuit Lifespan during Continuous Renal Replacement Therapy: A Prospective, Three-Arm, Randomized Controlled Study in Critically ill Acute Kidney Injury Patients with Sepsis (ChiCTR2600121436)
    P=N/A, N=258, West China Hospital of Sichuan University; West China Hospital of Sichuan University
    New trial
    |
    IL6 (Interleukin 6) • CRP (C-reactive protein)
    |
    nafamostat
    2ms
    Comparison of Anticoagulant Effects of Different Doses of Nafamostat in Continuous Renal Replacement Therapy (CRRT) in the Intensive Care Unit (ICU) (clinicaltrials.gov)
    P2, N=92, Recruiting, Zhujiang Hospital | Not yet recruiting --> Recruiting
    Enrollment open
    |
    nafamostat
    3ms
    Comparison of Anticoagulant Effects of Different Doses of Nafamostat in Continuous Renal Replacement Therapy (CRRT) in the Intensive Care Unit (ICU) (clinicaltrials.gov)
    P2, N=92, Not yet recruiting, Zhujiang Hospital
    New P2 trial
    |
    nafamostat
    3ms
    Single Dose Study, Pharmacokinetics of Oxycodone and PF614 Co-Administered With Nafamostat (PF614-MPAR-102) (clinicaltrials.gov)
    P1, N=30, Recruiting, Ensysce Biosciences | N=50 --> 30 | Trial completion date: Mar 2026 --> Dec 2026 | Trial primary completion date: Jan 2026 --> Jul 2026
    Enrollment change • Trial completion date • Trial primary completion date
    4ms
    Comparison of Anticoagulant Effects Between Nafamostat Mesylate and Sodium Citrate in Double Filtration Plasmapheresis (ChiCTR2600117445)
    P=N/A, N=140, Not yet recruiting, The First Affiliated Hospital of Army Medical University PLA; The First Affiliated Hospital of Army Medical University PLA
    New trial
    |
    nafamostat
    4ms
    A Randomized, Active-Controlled, Open-Label Clinical Study of Nafamostat Mesylate for Reducing Bleeding Risk in Maintenance Hemodialysis Patients at High Risk of Bleeding (ChiCTR2600116304)
    P=N/A, N=338, Not yet recruiting, The Seventh Affiliated Hospital Sun Yat-sen University; The Seventh Affiliated Hospital of Sun Yat-sen University
    New trial
    |
    nafamostat • enoxaparin sodium
    6ms
    Effect of extracorporeal anticoagulation with nafamostat mesilate and continuous renal replacement therapy on sepsis complicated with acute kidney injury. (PubMed, Int J Clin Pharmacol Ther)
    NM outperforms RCA in prolonging the hemofilter lifespan, reducing hemofilter replacement frequency, improving renal perfusion and renal function, and eliminating inflammatory mediators.
    Journal
    |
    IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha)
    |
    nafamostat
    7ms
    Multifaceted anticancer activity of nafamostat mesylate in human fibrosarcoma: first evidence of mitochondrial apoptosis and suppressed MMP-2/-9 mRNA expression. (PubMed, BMC Pharmacol Toxicol)
    This study provides the first evidence that nafamostat mesylate exerts multifaceted anticancer effects in HT1080 fibrosarcoma cells, targeting proliferation, migration, apoptosis, and invasion. These findings support the potential repurposing of nafamostat mesylate as a therapeutic agent for fibrosarcoma and warrant further preclinical investigations to evaluate its translational applicability.
    Journal
    |
    MMP2 (Matrix metallopeptidase 2) • MMP9 (Matrix metallopeptidase 9) • ANXA5 (Annexin A5)
    |
    nafamostat
    7ms
    Comparison of the efficacy and safety of nafamostat mesylate and heparin in blood purification therapy for patients with severe acute pancreatitis: A randomized controlled trial (ChiCTR2500111161)
    P4, N=140, Not yet recruiting, Weifang People's Hospital; Weifang People's Hospital
    New P4 trial
    |
    nafamostat
    7ms
    The Safety and Efficacy of Different Anticoagulation Strategies in Double Filtration Plasmapheresis Therapy (ChiCTR2500109547)
    P=N/A, N=300, Not yet recruiting, West China Hospital of Sichuan University; West China Hospital of Sichuan University
    New trial
    |
    nafamostat